Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.

Journal of veterinary internal medicine - 1 Jan 2000

Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M

Abstract excerpt

BACKGROUND: Imatinib mesylate is a small molecule targeted at dysregulated protein-tyrosine kinase. Mutation of c-kit exon 11, which induces constitutive phosphorylation of KIT, is one of the mechanisms for the development or progression of mast cell tumor (MCT) in dogs. The purpose of this study was to examine the therapeutic potential of imatinib mesylate in canine MCT. HYPOTHESIS: Imatinib mesylate has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dog Diseases

Share to Imatinib Mesylate

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 18564222
DOI: 10.1111/j.1939-1676.2008.00132.x

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.PMID 18564222Read ↗

Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.Semantic proximity Read ↗

Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.Semantic proximity Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.Semantic proximity Read ↗

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Semantic proximity Read ↗

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.Semantic proximity Read ↗

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.Semantic proximity Read ↗

The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell TumorsSemantic proximity Read ↗

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.Semantic proximity Read ↗

A decrease in ubiquitination and resulting prolonged life-span of KIT underlies the KIT overexpression-mediated imatinib resistance of KIT mutation-driven canine mast cell tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.